Fig. 3 | Scientific Reports

Fig. 3

From: Management of COVID-19 associated coagulopathy in critically ill patients and the risk of acquired von willebrand syndrome

Fig. 3

Comparison of ADAMTS-13, factor VIII, and factor IX in ECMO group and non-ECMO group.

Solid lines indicate the ECMO group, and dotted lines indicate the non-ECMO group.

*P < 0.05, **P < 0.01 for comparisons between the linked groups at each point. The gray area indicates the reference range.

Point 1 (P-1): day 1 (at intensive care unit admission in both groups, and before starting vvECMO in the ECMO group), Point 2 (P-2): day 3 or 4 (ECMO group: third day after starting vvECMO, non-ECMO group: day 3), and Point 3 (P-3): day 6 to 7 (ECMO group: sixth day after starting vvECMO, non-ECMO group: day 6 or 7).

ADAMTS-13, a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13; vv, venovenous; ECMO, extracorporeal membrane oxygenation.

Back to article page